ASPN

Across TCGA pan-cancer cohorts, ASPN Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASPN data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ASPN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ASPN expression acts as an unfavorable survival marker.

ACC, LGG, and PRAD are the cancer types where ASPN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.067	0.674	<.001	30	view →
LGG	OS	Median	All	0.306	0.811	.007	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	II,III,IV	0.192	0.691	.002	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ASPN–ACC (DFS)

Open the ACC breakdown →